PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.65%
Cash & equivalents declining -7.65% while TRVN's grows 35.14%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-7.65%
Cash + STI yoy 0.5-0.75x TRVN's -12.22%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Other current assets growth < half of TRVN's -49.25%. David Dodd sees a leaner approach to short-term items.
-5.46%
Below half of TRVN's -12.84%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.35%
Below half TRVN's -4.99%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Less than half of TRVN's 0.15%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
2.60%
Below half of TRVN's -3.81%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Below half of TRVN's -12.26%. Michael Burry sees a potential red flag for stagnation or capital shortage.
41.04%
50-75% of TRVN's 69.38%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.09%
Above 1.5x TRVN's 5.46%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.41%
Less than half of TRVN's -8.06%. David Dodd sees far fewer liability expansions relative to competitor.
4.74%
Higher Common Stock (Book Value) Growth compared to TRVN's zero value, indicating worse performance.
-3.50%
≥ 1.5x TRVN's -2.10%. David Dodd sees higher yoy retained profits than competitor.
-4.99%
Less than half of TRVN's 55.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-23.90%
≥ 1.5x TRVN's -14.63%. David Dodd sees stronger capital base growth than competitor.
-5.18%
Below half TRVN's -12.26%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.42%
Less than half of TRVN's -293.88%. David Dodd sees better deleveraging or stronger cash buildup than competitor.